The 41st





Medicinal Chemistry Symposium

The Frontiers of Medicinal Chemistry: Capability, Skills and Creativity



November 20 [Wed] - 22 [Fri], 2024



Kyoto terrsa

(https://www.kyoto-terrsa.or.jp/)



CD73 - new target for cancer imaging

Anna Junker Werner Siemens Imaging Center

Transport and inhibition mechanism of the human SGLT2-MAP17 glucose transporter

Tomoya Akashi Mitsubishi Tanabe Pharma Corporation



Building a platform for the renaissance of natural product drug discovery

Satoshi Ichikawa Hokkaido University

How to open unexplored chemical spaces?

Masanobu Uchiyama The University of Tokyo

Cancer therapy using photochemical reactions

Mikako Ogawa Hokkaido University

Understanding and designing passive cell membrane-permeable peptides.

Shinsuke Sando The University of Tokyo

Small molecule drug discovery targeting mRNA
-Toward the creation of small molecule drugs that
selectively bind to RNA structures

Shingo Nakamura Veritas In Silico Inc.

Research and Development of mRNA Vaccine (DAICHIRONAR FOR INTRAMUSCULAR INJECTION)

Takako Niwa DAIICHI SANKYO COMPANY, LIMITED

R&D of anti-FGF23 antibody, burosumab
-Blockbuster from Japan with life-changing value-

Yuji Yamazaki Kyowa Kirin Co., Ltd.



Abstract submission deadline September $20^{\rm [Fri]}_{,2024}$

Pre-registration deadline
October 17 [Thu], 2024

Please refer to the website for details. https://www.mcs2024.jp

Secretariat

Executive Committee Chairperson: **Kenji Yamawaki** (Shionogi & Co., Ltd.) 3-1-1, Futaba-cho, Toyonaka-shi, Osaka 561-0825, Japan

Management cooperation

KOHMURA Inc.

3 Miwa Purintopia, Gifu-shi, Gifu, 501-2517, Japan E-mail:mcs2024@kohmura.co.jp

